Warning letter
Snyder Mark Drugs Roselle, Inc. d.b.a. Mark Drugs Pharmacy: warning letter of Feb 27, 2018
FDA warning letter 547409 · Detroit District Office
Key facts
| Reference number | 547409 |
|---|---|
| Company | Snyder Mark Drugs Roselle, Inc. d.b.a. Mark Drugs Pharmacy |
| Subject | Compounding Pharmacy/Adulterated Drug Products |
| Issue date | Feb 27, 2018 |
| Posted date | Feb 27, 2018 |
| Issuing office | Detroit District Office |
| Product type | Drugs |
| CFR sections cited | 211.28(a), 211.42(c)(10)(iv), 211.113(b), 211.42(c)(10)(vi), 210.1(b), 211.167(a), 211.166(a), 200.10(b) |
| Inspection city | Roselle |
| Inspection ZIP | 60172 |
| Inspection start date | Apr 26, 2017 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: